Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Mirati Therapeutics downgraded to Underperform from Neutral at BofA » 06:04
11/17/20
11/17
06:04
11/17/20
06:04
MRTX

Mirati Therapeutics

$229.02 /

-0.21 (-0.09%)

BofA analyst Jason…

BofA analyst Jason Gerberry downgraded Mirati Therapeutics to Underperform from Neutral with a $196 price target.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$229.02 /

-0.21 (-0.09%)

MRTX Mirati Therapeutics
$229.02 /

-0.21 (-0.09%)

11/10/20 Guggenheim
Mirati Therapeutics downgraded to Neutral from Buy at Guggenheim
11/10/20 Jefferies
Mirati Therapeutics downgraded to Hold from Buy at Jefferies
11/09/20 H.C. Wainwright
Mirati Therapeutics price target raised to $265 from $233 at H.C. Wainwright
11/05/20 Oppenheimer
Mirati Therapeutics price target raised to $260 from $225 at Oppenheimer
MRTX Mirati Therapeutics
$229.02 /

-0.21 (-0.09%)

  • 28
    Oct
  • 10
    Jan
MRTX Mirati Therapeutics
$229.02 /

-0.21 (-0.09%)

Downgrade
Mirati Therapeutics downgraded to Neutral from Buy at Guggenheim » 07:58
11/10/20
11/10
07:58
11/10/20
07:58
MRTX

Mirati Therapeutics

$227.18 /

-3.19 (-1.38%)

Guggenheim analyst…

Guggenheim analyst Michael Schmidt downgraded Mirati Therapeutics to Neutral from Buy with a $230 price target.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$227.18 /

-3.19 (-1.38%)

MRTX Mirati Therapeutics
$227.18 /

-3.19 (-1.38%)

11/10/20 Jefferies
Mirati Therapeutics downgraded to Hold from Buy at Jefferies
11/09/20 H.C. Wainwright
Mirati Therapeutics price target raised to $265 from $233 at H.C. Wainwright
11/05/20 Oppenheimer
Mirati Therapeutics price target raised to $260 from $225 at Oppenheimer
11/05/20 Piper Sandler
Piper says Mirati now 'prime' biotech takeout candidate, boosts target
MRTX Mirati Therapeutics
$227.18 /

-3.19 (-1.38%)

  • 28
    Oct
  • 10
    Jan
MRTX Mirati Therapeutics
$227.18 /

-3.19 (-1.38%)

Downgrade
Mirati Therapeutics downgraded to Hold from Buy at Jefferies » 07:57
11/10/20
11/10
07:57
11/10/20
07:57
MRTX

Mirati Therapeutics

$227.18 /

-3.19 (-1.38%)

, AMGN

Amgen

$234.79 /

+3.12 (+1.35%)

Jefferies analyst Maury…

Jefferies analyst Maury Raycroft downgraded Mirati Therapeutics (MRTX) to Hold from Buy with a price target of $208, up from $206. While recent stock momentum makes sense given the upside potential for a large KRAS market opportunity, he now thinks the current valuation is "extended," Raycroft tells investors. While he generally thought Mirati's data at the "Triple Meeting" were in-line to better than Amgen (AMGN), he also thinks the total clinical data primarily support mono-therapy KRAS G12C covalent inhibition potential and "only justify" a range-bound valuation, the analyst added.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$227.18 /

-3.19 (-1.38%)

AMGN Amgen
$234.79 /

+3.12 (+1.35%)

MRTX Mirati Therapeutics
$227.18 /

-3.19 (-1.38%)

11/09/20 H.C. Wainwright
Mirati Therapeutics price target raised to $265 from $233 at H.C. Wainwright
11/05/20 Oppenheimer
Mirati Therapeutics price target raised to $260 from $225 at Oppenheimer
11/05/20 Piper Sandler
Piper says Mirati now 'prime' biotech takeout candidate, boosts target
11/02/20 H.C. Wainwright
Mirati Therapeutics price target lowered to $233 from $238 at H.C. Wainwright
AMGN Amgen
$234.79 /

+3.12 (+1.35%)

11/04/20 Citi
Amgen shares unlikely to move much on Bristol trial success, says Citi
11/02/20 Mizuho
Amgen price target lowered to $200 from $215 at Mizuho
10/29/20 SVB Leerink
Amgen price target lowered to $243 from $261 at SVB Leerink
10/29/20 JPMorgan
Amgen price target lowered to $222 from $232 at JPMorgan
MRTX Mirati Therapeutics
$227.18 /

-3.19 (-1.38%)

AMGN Amgen
$234.79 /

+3.12 (+1.35%)

  • 28
    Oct
  • 10
    Jan
AMGN Amgen
$234.79 /

+3.12 (+1.35%)

MRTX Mirati Therapeutics
$227.18 /

-3.19 (-1.38%)

AMGN Amgen
$234.79 /

+3.12 (+1.35%)

AMGN Amgen
$234.79 /

+3.12 (+1.35%)

Recommendations
Mirati Therapeutics price target raised to $265 from $233 at H.C. Wainwright » 06:12
11/09/20
11/09
06:12
11/09/20
06:12
MRTX

Mirati Therapeutics

$230.74 /

-6.17 (-2.60%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White raised the firm's price target on Mirati Therapeutics to $265 from $233 and keeps a Buy rating on the shares following the company's Q3 results. The analyst says adagrasib remains on track.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$230.74 /

-6.17 (-2.60%)

MRTX Mirati Therapeutics
$230.74 /

-6.17 (-2.60%)

11/05/20 Oppenheimer
Mirati Therapeutics price target raised to $260 from $225 at Oppenheimer
11/05/20 Piper Sandler
Piper says Mirati now 'prime' biotech takeout candidate, boosts target
11/02/20 H.C. Wainwright
Mirati Therapeutics price target lowered to $233 from $238 at H.C. Wainwright
10/29/20
Fly Intel: Top five analyst initiations
MRTX Mirati Therapeutics
$230.74 /

-6.17 (-2.60%)

  • 28
    Oct
  • 10
    Jan
MRTX Mirati Therapeutics
$230.74 /

-6.17 (-2.60%)

Recommendations
Mirati Therapeutics price target raised to $260 from $225 at Oppenheimer » 07:09
11/05/20
11/05
07:09
11/05/20
07:09
MRTX

Mirati Therapeutics

$234.75 /

+13.86 (+6.27%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson raised the firm's price target on Mirati Therapeutics to $260 from $225 and keeps an Outperform rating on the shares. The analyst notes that the company reported Q3 R&D expenses of $79.9M and G&A expenses of $20.2M, plus $11.4M license and collaboration revenues, driving Q3 EPS of ($1.96). Mirati is in a strong cash position with $579.1M cash and cash equivalents, and the additional $879.7M estimated net proceeds from recently completed equity offering further strengthen its balance sheet, Olson adds.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

11/05/20 Piper Sandler
Piper says Mirati now 'prime' biotech takeout candidate, boosts target
11/02/20 H.C. Wainwright
Mirati Therapeutics price target lowered to $233 from $238 at H.C. Wainwright
10/29/20
Fly Intel: Top five analyst initiations
10/29/20 Barclays
Mirati Therapeutics price target raised to $244 from $143 at Barclays
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

  • 28
    Oct
  • 10
    Jan
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

Recommendations
Piper says Mirati now 'prime' biotech takeout candidate, boosts target » 05:02
11/05/20
11/05
05:02
11/05/20
05:02
MRTX

Mirati Therapeutics

$234.75 /

+13.86 (+6.27%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren raised the firm's price target on Mirati Therapeutics to $260 from $210 and keeps an Overweight rating on the shares. The stock closed Wednesday up 6% to $234.68. Mirati shares are trading like the company is going to be acquired, and "rightfully so" as adagrasib appears to be the best-in-class KRAS G12C, Van Buren tells investors in a research note. The analyst has a high level of confidence in adagrasib's approvability and its potential to take a "majority share" of the $5B-plus KRAS G12C market. Most large pharma companies that play in the solid tumor/targeted oncology area are interested in an asset like adagrasib and an acquisition "could come in the very near future," says Van Buren. He thinks Mirati Therapeutics has become the "prime biotech takeout candidate."

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

11/02/20 H.C. Wainwright
Mirati Therapeutics price target lowered to $233 from $238 at H.C. Wainwright
10/29/20
Fly Intel: Top five analyst initiations
10/29/20 Barclays
Mirati Therapeutics price target raised to $244 from $143 at Barclays
10/29/20 Credit Suisse
Mirati Therapeutics reinstated with an Outperform at Credit Suisse
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

  • 28
    Oct
  • 10
    Jan
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

Earnings
Mirati Therapeutics reports Q3 EPS ($1.96), consensus ($1.97) » 16:58
11/04/20
11/04
16:58
11/04/20
16:58
MRTX

Mirati Therapeutics

$234.75 /

+13.86 (+6.27%)

Reports Q3 revenue…

Reports Q3 revenue $11.4M, consensus $2.69M. "Q3 was notable for significant progress and we have begun the fourth quarter with positive momentum. At the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics last week, we presented preliminary adagrasib data across multiple tumors, which highlighted the potential for this exciting and differentiated program. We have completed enrollment in our Phase 2 potentially registration-enabling monotherapy trial in 2nd or 3rd line non-small cell lung cancer patients, which will enable our anticipated NDA filing to the FDA for accelerated approval in the second half of 2021." said CEO Charles Baum. "We presented the first preclinical data for MRTX1133, a potentially first in class, potent, selective and reversible inhibitor of KRAS G12D in both its active and inactive states. MRTX1133 demonstrated significant tumor regression in several preclinical tumor models, and we anticipate filing an IND in the first half of 2021. Our recent public offering provides the resources to accelerate and expand development across our pipeline, including sitravatinib, adagrasib, MRTX1133 and discovery programs, as we continue to build our organization, prepare for commercialization and strive to bring novel therapies to cancer patients and their families."

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

11/02/20 H.C. Wainwright
Mirati Therapeutics price target lowered to $233 from $238 at H.C. Wainwright
10/29/20
Fly Intel: Top five analyst initiations
10/29/20 Barclays
Mirati Therapeutics price target raised to $244 from $143 at Barclays
10/29/20 Credit Suisse
Mirati Therapeutics reinstated with an Outperform at Credit Suisse
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

  • 28
    Oct
  • 10
    Jan
MRTX Mirati Therapeutics
$234.75 /

+13.86 (+6.27%)

Recommendations
Mirati Therapeutics price target lowered to $233 from $238 at H.C. Wainwright » 06:16
11/02/20
11/02
06:16
11/02/20
06:16
MRTX

Mirati Therapeutics

$216.45 /

-3.51 (-1.60%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White lowered the firm's price target on Mirati Therapeutics to $233 from $238 and keeps a Buy rating on the shares to reflect dilution from the recent stock offering.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$216.45 /

-3.51 (-1.60%)

MRTX Mirati Therapeutics
$216.45 /

-3.51 (-1.60%)

10/29/20
Fly Intel: Top five analyst initiations
10/29/20 Barclays
Mirati Therapeutics price target raised to $244 from $143 at Barclays
10/29/20 Credit Suisse
Mirati Therapeutics reinstated with an Outperform at Credit Suisse
10/26/20 SVB Leerink
Mirati Therapeutics price target raised to $195 from $134 at SVB Leerink
MRTX Mirati Therapeutics
$216.45 /

-3.51 (-1.60%)

  • 28
    Oct
  • 10
    Jan
MRTX Mirati Therapeutics
$216.45 /

-3.51 (-1.60%)

Over a month ago
Initiation
Fly Intel: Top five analyst initiations » 09:51
10/29/20
10/29
09:51
10/29/20
09:51
BNTX

BioNTech

$79.99 /

+2.36 (+3.04%)

, ANGI

Angi Homeservices

$10.77 /

+0.115 (+1.08%)

, ADCT

ADC Therapeutics

$28.99 /

+0.36 (+1.26%)

, MRTX

Mirati Therapeutics

$203.41 /

+1.02 (+0.50%)

, SVC

Service Properties

$6.95 /

-0.155 (-2.18%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioNTech (BNTX) initiated with a Buy at Commerzbank. 2. Angi Homeservices (ANGI) initiated with an Outperform at Credit Suisse. 3. ADC Therapeutics (ADCT) initiated with a Buy at H.C. Wainwright. 4. Mirati Therapeutics (MRTX) reinstated with an Outperform at Credit Suisse. 5. Service Properties (SVC) initiated with a Neutral at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SVC Service Properties
$6.95 /

-0.155 (-2.18%)

MRTX Mirati Therapeutics
$203.41 /

+1.02 (+0.50%)

BNTX BioNTech
$79.99 /

+2.36 (+3.04%)

ANGI Angi Homeservices
$10.77 /

+0.115 (+1.08%)

ADCT ADC Therapeutics
$28.99 /

+0.36 (+1.26%)

BNTX BioNTech
$79.99 /

+2.36 (+3.04%)

10/29/20 Commerzbank
BioNTech initiated with a Buy at Commerzbank
10/14/20 SVB Leerink
BioNTech price target raised to $69 from $62 at SVB Leerink
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
ANGI Angi Homeservices
$10.77 /

+0.115 (+1.08%)

10/29/20 Credit Suisse
IAC price target raised to $199 from $160 at Credit Suisse
10/29/20 Credit Suisse
Angi Homeservices initiated with an Outperform at Credit Suisse
09/24/20 Piper Sandler
Angi Homeservices initiated with a Neutral at Piper Sandler
09/15/20 Jefferies
IAC's key segments saw sequential acceleration in August, says Jefferies
ADCT ADC Therapeutics
$28.99 /

+0.36 (+1.26%)

10/29/20 H.C. Wainwright
ADC Therapeutics initiated with a Buy at H.C. Wainwright
06/09/20 Morgan Stanley
ADC Therapeutics initiated with an Overweight at Morgan Stanley
06/09/20 Cowen
ADC Therapeutics initiated with an Outperform at Cowen
06/09/20 BofA
ADC Therapeutics initiated with a Buy at BofA
MRTX Mirati Therapeutics
$203.41 /

+1.02 (+0.50%)

10/29/20 Barclays
Mirati Therapeutics price target raised to $244 from $143 at Barclays
10/29/20 Credit Suisse
Mirati Therapeutics reinstated with an Outperform at Credit Suisse
10/26/20 SVB Leerink
Mirati Therapeutics price target raised to $195 from $134 at SVB Leerink
10/26/20 Oppenheimer
Mirati Therapeutics price target raised to $225 from $190 at Oppenheimer
SVC Service Properties
$6.95 /

-0.155 (-2.18%)

10/29/20 BTIG
Service Properties initiated with a Neutral at BTIG
10/21/20 B. Riley Securities
Service Properties price target lowered to $12 from $14 at B. Riley Securities
06/05/20 B. Riley Securities
Braemar Hotels downgraded to Neutral on valuaton at B. Riley FBR
05/12/20 B. Riley Securities
Service Properties price target lowered to $13 from $17 at B. Riley FBR
MRTX Mirati Therapeutics
$203.41 /

+1.02 (+0.50%)

BNTX BioNTech
$79.99 /

+2.36 (+3.04%)

ANGI Angi Homeservices
$10.77 /

+0.115 (+1.08%)

ADCT ADC Therapeutics
$28.99 /

+0.36 (+1.26%)

  • 28
    Oct
  • 24
    Sep
  • 23
    Jul
  • 15
    May
  • 06
    Feb
  • 10
    Jan
BNTX BioNTech
$79.99 /

+2.36 (+3.04%)

MRTX Mirati Therapeutics
$203.41 /

+1.02 (+0.50%)

BNTX BioNTech
$79.99 /

+2.36 (+3.04%)

ANGI Angi Homeservices
$10.77 /

+0.115 (+1.08%)

BNTX BioNTech
$79.99 /

+2.36 (+3.04%)

ANGI Angi Homeservices
$10.77 /

+0.115 (+1.08%)

ADCT ADC Therapeutics
$28.99 /

+0.36 (+1.26%)

Recommendations
Mirati Therapeutics price target raised to $244 from $143 at Barclays » 06:32
10/29/20
10/29
06:32
10/29/20
06:32
MRTX

Mirati Therapeutics

$202.32 /

-7.45 (-3.55%)

Barclays analyst Gena…

Barclays analyst Gena Wang raised the firm's price target on Mirati Therapeutics to $244 from $143 and keeps an Overweight rating on the shares. Key opinion leaders the analyst spoke to were impressed with adagrasib's overall response rates of 45%, the depth of response, and efficacy in STX11 co-mutation patients. The firm's new target reflects a higher probability of success and larger market share of adagrasib in non-small-cell lung carcinoma and market potential for MRTX1133, Wang tells investors in a research note.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$202.32 /

-7.45 (-3.55%)

MRTX Mirati Therapeutics
$202.32 /

-7.45 (-3.55%)

10/29/20 Credit Suisse
Mirati Therapeutics reinstated with an Outperform at Credit Suisse
10/26/20 SVB Leerink
Mirati Therapeutics price target raised to $195 from $134 at SVB Leerink
10/26/20 Oppenheimer
Mirati Therapeutics price target raised to $225 from $190 at Oppenheimer
10/26/20 Goldman Sachs
Mirati Therapeutics price target raised to $267 from $152 at Goldman Sachs
MRTX Mirati Therapeutics
$202.32 /

-7.45 (-3.55%)

  • 28
    Oct
  • 10
    Jan
MRTX Mirati Therapeutics
$202.32 /

-7.45 (-3.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.